ANXA13 promotes cell proliferation and invasion and attenuates apoptosis in renal cell carcinoma

[1]  C. Criscitiello,et al.  Evolution of low HER2 expression between early and advanced-stage breast cancer. , 2022, European journal of cancer.

[2]  Cong Zhang,et al.  Annexin A13 predicts poor prognosis for lung adenocarcinoma patients and accelerates the proliferation and migration of lung adenocarcinoma cells by modulating epithelial–mesenchymal transition , 2020, Fundamental & clinical pharmacology.

[3]  N. Singla.  A New Therapeutic Era for Metastatic Renal Cell Carcinoma: Call for a New Prognostic Model. , 2020, JAMA oncology.

[4]  Minhong Wang,et al.  New Preoperative Nomogram Using the Centrality Index to Predict High Nuclear Grade Clear Cell Renal Carcinoma , 2019, Cancer management and research.

[5]  C. Porta,et al.  Renal cell carcinoma treatment after first-line combinations. , 2019, The Lancet. Oncology.

[6]  Ronak H Shah,et al.  Precision oncology: lessons learned and challenges for the future , 2019, Cancer management and research.

[7]  S. Yalcin,et al.  Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma , 2019, Cancer management and research.

[8]  Lorenzo Marconi,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.

[9]  B. Shen,et al.  Expression of miR-21 and miR-138 in colon cancer and its effect on cell proliferation and prognosis , 2018, Oncology letters.

[10]  Yuan Yang,et al.  MicroRNA-197-3p acts as a prognostic marker and inhibits cell invasion in hepatocellular carcinoma , 2018, Oncology letters.

[11]  Wei Jiang,et al.  Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer , 2018, Oncology letters.

[12]  D. Heng,et al.  Prognostication in Kidney Cancer: Recent Advances and Future Directions. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[14]  R. Montironi,et al.  Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer , 2018, Expert review of molecular diagnostics.

[15]  B. Curti.  Immunotherapy in Advanced Renal Cancer - Is Cure Possible? , 2018, The New England journal of medicine.

[16]  Wei Zhang,et al.  Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics. , 2018, Chemical Society reviews.

[17]  M. P. Laguna.  Re: Partial Nephrectomy versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-Analysis of Comparative Studies. , 2017, The Journal of urology.

[18]  B. Rini,et al.  Treatment of renal cell carcinoma: Current status and future directions , 2017, CA: a cancer journal for clinicians.

[19]  K. Badani,et al.  Heterogeneity in renal cell carcinoma. , 2017, Urologic oncology.

[20]  Chad A. LaGrange,et al.  Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  L. Dai,et al.  Annexin A13 promotes tumor cell invasion in vitro and is associated with metastasis in human colorectal cancer , 2017, Oncotarget.

[22]  Xin-yang Wang,et al.  CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9. , 2015, International journal of oncology.

[23]  P. Krammer,et al.  The Tolerogenic Function of Annexins on Apoptotic Cells Is Mediated by the Annexin Core Domain , 2015, The Journal of Immunology.

[24]  X. Qu,et al.  Cancer biomarker detection: recent achievements and challenges. , 2015, Chemical Society reviews.

[25]  P. Delvenne,et al.  NF-κB-induced KIAA1199 promotes survival through EGFR signalling , 2014, Nature Communications.

[26]  S. Hancock,et al.  Kidney cancer, version 2.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[27]  Yun-peng Liu,et al.  ECHS1 acts as a novel HBsAg-binding protein enhancing apoptosis through the mitochondrial pathway in HepG2 cells. , 2013, Cancer letters.

[28]  S. Shariat,et al.  Biomarkers in personalised treatment of renal-cell carcinoma. , 2012, The Lancet. Oncology.

[29]  M. Tabuchi,et al.  Whole rat DNA array survey for candidate genes related to hypertension in kidneys from three spontaneously hypertensive rat substrains at two stages of age and with hypotensive induction caused by hydralazine hydrochloride. , 2011, Experimental and therapeutic medicine.

[30]  M. Paulsson,et al.  Identification of Novel Binding Partners (Annexins) for the Cell Death Signal Phosphatidylserine and Definition of Their Recognition Motif* , 2010, The Journal of Biological Chemistry.

[31]  W. Hop,et al.  High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas , 2007, Cytogenetic and Genome Research.

[32]  J. Lam,et al.  Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[34]  J. Turnay,et al.  Structure-function relationship in annexin A13, the founder member of the vertebrate family of annexins. , 2005, The Biochemical journal.

[35]  S. Moss,et al.  Annexins: from structure to function. , 2002, Physiological reviews.

[36]  C. Sheehan,et al.  Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[38]  K A Schafer,et al.  The Cell Cycle: A Review , 1998, Veterinary pathology.

[39]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[40]  M. Barbareschi,et al.  p21/WAF1/CIP1 EXPRESSION IN NORMAL MUCOSA AND IN ADENOMAS AND ADENOCARCINOMAS OF THE COLON: ITS RELATIONSHIP WITH DIFFERENTIATION , 1996, The Journal of pathology.

[41]  Ruth J. Muschel,et al.  Cell Cycle-dependent Regulation of the Cyclin B1 Promoter (*) , 1995, The Journal of Biological Chemistry.

[42]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  B. Saville,et al.  Detection of antisense RNA transcripts by strand-specific RT-PCR. , 2010, Methods in molecular biology.

[44]  A. D’Andrea,et al.  The Fanconi anaemia/BRCA pathway , 2003, Nature Reviews Cancer.

[45]  G. Heppner.  Tumor heterogeneity. , 1984, Cancer research.